Teva Pharmaceutical Industries annual operating expenses
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Operating Expenses Growth & History (TEVA)
Teva Pharmaceutical Industries's operating expenses was $6.78B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.78B | −$1.59B | −18.96% |
| 2024 | 2024-12-31 | $8.37B | $1.16B | +16.01% |
| 2023 | 2023-12-31 | $7.21B | −$1.96B | −21.35% |
| 2022 | 2022-12-31 | $9.17B | $3.29B | +56.01% |
| 2021 | 2021-12-31 | $5.88B | −$5.42B | −47.97% |
| 2020 | 2020-12-31 | $11.30B | $3.32B | +41.58% |
| 2019 | 2019-12-31 | $7.98B | −$1.95B | −19.66% |
| 2018 | 2018-12-31 | $9.93B | −$18.17B | −64.65% |
| 2017 | 2017-12-31 | $28.10B | $18.60B | +195.81% |
| 2016 | 2016-12-31 | $9.50B | — | — |
| 2013 | 2013-12-31 | $9.06B | $611.0M | +7.23% |
| 2012 | 2012-12-31 | $8.45B | $2.04B | +31.86% |
| 2011 | 2011-12-31 | $6.41B | $1.21B | +23.33% |
| 2010 | 2010-12-31 | $5.19B | $232.0M | +4.68% |
| 2009 | 2009-12-31 | $4.96B | $139.0M | +2.88% |
| 2008 | 2008-12-31 | $4.82B | $2.34B | +94.32% |
| 2007 | 2007-12-31 | $2.48B | — | — |
Teva Pharmaceutical Industries quarterly operating expenses
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.38B | $737.0M | +44.75% |
| Q1 2026 | 2026-03-31 | $1.32B | −$38.0M | −2.80% |
| Q4 2025 | 2025-12-31 | $2.35B | $204.0M | +9.49% |
| Q3 2025 | 2025-09-30 | $1.42B | −$777.0M | −35.33% |
| Q2 2025 | 2025-06-30 | $1.65B | −$382.0M | −18.83% |
| Q1 2025 | 2025-03-31 | $1.36B | −$631.0M | −31.72% |
| Q4 2024 | 2024-12-31 | $2.15B | $490.0M | +29.52% |
| Q3 2024 | 2024-09-30 | $2.20B | $692.0M | +45.92% |
| Q2 2024 | 2024-06-30 | $2.03B | −$421.0M | −17.18% |
| Q1 2024 | 2024-03-31 | $1.99B | $394.0M | +24.70% |
| Q4 2023 | 2023-12-31 | $1.66B | −$1.05B | −38.77% |
| Q3 2023 | 2023-09-30 | $1.51B | $262.0M | +21.04% |
| Q2 2023 | 2023-06-30 | $2.45B | −$311.0M | −11.26% |
| Q1 2023 | 2023-03-31 | $1.59B | −$858.0M | −34.98% |
| Q4 2022 | 2022-12-31 | $2.71B | $739.0M | +37.47% |
| Q3 2022 | 2022-09-30 | $1.25B | $74.0M | +6.32% |
| Q2 2022 | 2022-06-30 | $2.76B | $1.47B | +113.87% |
| Q1 2022 | 2022-03-31 | $2.45B | $1.01B | +69.88% |
| Q4 2021 | 2021-12-31 | $1.97B | $330.0M | +20.10% |
| Q3 2021 | 2021-09-30 | $1.17B | −$5.02B | −81.09% |
| Q2 2021 | 2021-06-30 | $1.29B | −$299.0M | −18.81% |
| Q1 2021 | 2021-03-31 | $1.44B | −$428.0M | −22.86% |
| Q4 2020 | 2020-12-31 | $1.64B | −$168.0M | −9.28% |
| Q3 2020 | 2020-09-30 | $6.19B | $4.28B | +224.12% |
| Q2 2020 | 2020-06-30 | $1.59B | −$947.0M | −37.33% |
| Q1 2020 | 2020-03-31 | $1.87B | $150.0M | +8.71% |
| Q4 2019 | 2019-12-31 | $1.81B | −$3.33B | −64.75% |
| Q3 2019 | 2019-09-30 | $1.91B | −$50.0M | −2.55% |
| Q2 2019 | 2019-06-30 | $2.54B | $490.0M | +23.94% |
| Q1 2019 | 2019-03-31 | $1.72B | $932.0M | +117.97% |
| Q4 2018 | 2018-12-31 | $5.13B | −$10.33B | −66.79% |
| Q3 2018 | 2018-09-30 | $1.96B | −$260.0M | −11.71% |
| Q2 2018 | 2018-06-30 | $2.05B | −$6.50B | −76.04% |
| Q1 2018 | 2018-03-31 | $790.0M | −$1.08B | −57.87% |
| Q4 2017 | 2017-12-31 | $15.46B | $12.14B | +365.55% |
| Q3 2017 | 2017-09-30 | $2.22B | $185.0M | +9.09% |
| Q2 2017 | 2017-06-30 | $8.54B | $6.03B | +239.51% |
| Q1 2017 | 2017-03-31 | $1.88B | $249.0M | +15.31% |
| Q4 2016 | 2016-12-31 | $3.32B | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $2.04B | $275.0M | +15.62% |
| Q2 2016 · Jun 30 | 2016-06-30 | $2.52B | $276.0M | +12.32% |
| Q1 2016 · Mar 31 | 2016-03-31 | $1.63B | −$461.0M | −22.09% |
| Q3 2016 · Sep 30 | 2015-09-30 | $1.76B | $64.0M | +3.77% |
| Q2 2016 · Jun 30 | 2015-06-30 | $2.24B | $504.0M | +29.03% |
| Q1 2016 · Mar 31 | 2015-03-31 | $2.09B | $362.0M | +20.99% |
| Q3 2014 | 2014-09-30 | $1.70B | −$132.0M | −7.22% |
| Q2 2014 | 2014-06-30 | $1.74B | −$1.44B | −45.39% |
| Q1 2014 | 2014-03-31 | $1.73B | $9.0M | +0.52% |
| Q4 2013 | 2013-12-31 | $2.33B | −$121.0M | −4.93% |
| Q3 2013 | 2013-09-30 | $1.83B | −$832.0M | −31.27% |
| Q2 2013 | 2013-06-30 | $3.18B | $1.53B | +92.67% |
| Q1 2013 | 2013-03-31 | $1.72B | $35.0M | +2.08% |
| Q4 2012 | 2012-12-31 | $2.46B | $184.0M | +8.10% |
| Q3 2012 | 2012-09-30 | $2.66B | $1.45B | +119.74% |
| Q2 2012 | 2012-06-30 | $1.65B | $47.0M | +2.93% |
| Q1 2012 | 2012-03-31 | $1.68B | $360.0M | +27.25% |
| Q4 2011 | 2011-12-31 | $2.27B | $581.0M | +34.38% |
| Q3 2011 | 2011-09-30 | $1.21B | −$68.0M | −5.32% |
| Q2 2011 | 2011-06-30 | $1.60B | $557.0M | +53.25% |
| Q1 2011 | 2011-03-31 | $1.32B | $142.0M | +12.04% |
| Q4 2010 | 2010-12-31 | $1.69B | $3.0M | +0.18% |
| Q3 2010 | 2010-09-30 | $1.28B | $104.0M | +8.85% |
| Q2 2010 | 2010-06-30 | $1.05B | −$21.0M | −1.97% |
| Q1 2010 | 2010-03-31 | $1.18B | $146.0M | +14.13% |
| Q4 2009 | 2009-12-31 | $1.69B | −$324.0M | −16.11% |
| Q3 2009 | 2009-09-30 | $1.18B | $305.0M | +35.06% |
| Q2 2009 | 2009-06-30 | $1.07B | $200.0M | +23.07% |
| Q1 2009 | 2009-03-31 | $1.03B | −$42.0M | −3.91% |
| Q4 2008 | 2008-12-31 | $2.01B | — | — |
| Q3 2008 | 2008-09-30 | $870.0M | — | — |
| Q2 2008 | 2008-06-30 | $867.0M | — | — |
| Q1 2008 | 2008-03-31 | $1.07B | — | — |
Teva Pharmaceutical Industries operating expenses trends
Over the last five fiscal years, Teva Pharmaceutical Industries's operating expenses decreased from $11.30B to $6.78B, a change of −$4.52B. The latest reported quarter, Q2 2026, shows $2.38B.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗